CPRX Stock Analysis: Buy, Sell, or Hold?
CPRX - Catalyst Pharmaceutical Inc.
$31.28
0.03 (0.10%)
▲
5d:
+0.39%
30d:
+20.59%
90d:
+28.72%
HOLD
MODERATE Confidence
Analysis Updated: May 21, 2026 12:00 AM ET
Earnings: May 11, 2026
0d
Get Alerted When CPRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CPRX is fairly valued with market pricing in 4.1% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: CPRX is fairly valued with market pricing in 4.1% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$38.40
Based on 6.8% avg growth
INTRINSIC VALUE TODAY
$23.84
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CPRX is currently trading at $31.28, which is considered extended relative to its 30-day fair value range of $26.73 to $31.16. From a valuation perspective, the stock is trading at a premium (Forward PE: 10.0) compared to its historical average (8.8). At these levels, the market is pricing in 4.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CPRX is in a strong downtrend. The price is currently testing key support at $31.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CPRX is in a strong downtrend. The price is currently testing key support at $31.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$26.73 -
$31.16
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.1%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($33.30)
- NEUTRAL: Market pricing in 4.1% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$26.73 -
$31.16
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$31.00
Resistance Level
$31.36
Current Trend
Strong Downtrend
Technical data as of
May 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.98
Wall Street Target
$33.30
(+6.5%)
Revenue Growth (YoY)
5.6%
Earnings Growth (YoY)
11.1%
Profit Margin
37.1%
Valuation Premium vs History
+4.1% premium
PE vs Historical
10.0 vs 8.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.1%
(market-implied from PE analysis)
1-Year Target
$32.56
(+4%)
2-Year Target
$33.90
(+8%)
3-Year Target
$35.29
(+13%)
3-Yr Target (if PE normalizes)
(PE: 10→9)
PE COMPRESSION
$31.13
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 9.7%)
$90.94
(+191%)
Base:
(SPY PE: 10.0, Growth: 9.7%)
$41.26
(+32%)
Bear:
(PE: 8.5, Growth: 9.7%)
$35.07
(+12%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 18.06 | Current EPS (TTM): $1.73
Bull Case
$62.30
(+99%)
Analyst growth 81.2%, PE expands to 19.9
Base Case
$56.64
(+81%)
Market implied 81.2%, PE stable at 18.1
Bear Case
$21.25
(-32%)
Severe decline -20.0%, PE contracts to 15.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: May 21, 2026 6:00 PM ET
Data refreshes hourly during market hours. Next update: 7:00 PM
Data refreshes hourly during market hours. Next update: 7:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CPRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Molly Harper
SELL
26746 shares
2025-12-12
Carmen Jeffrey Del
SELL
10983 shares
2025-11-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$90 | 59 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 61 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 51 HOLD |
